TipRanks

Notifications

Berenberg Bank Keeps a Hold Rating on Merck & Company (MRK)

Berenberg Bank analyst Luisa Hector maintained a Hold rating on Merck & Company (MRKResearch Report) on November 22 and set a price target of $92.00. The company’s shares closed last Wednesday at $82.17.

According to TipRanks.com, Hector is a 2-star analyst with an average return of 4.7% and a 71.4% success rate. Hector covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Bristol Myers, and Novartis.

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $96.36, a 16.4% upside from current levels. In a report issued on November 19, BMO Capital also initiated coverage with a Hold rating on the stock with a $91.00 price target.

See the top stocks recommended by analysts >>

Merck & Company’s market cap is currently $209.1B and has a P/E ratio of 28.80. The company has a Price to Book ratio of 58.12.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRK in relation to earlier this year. Earlier this month, Kenneth Frazier, the Executive Chair of MRK sold 663,881 shares for a total of $54,607,864.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Read More on MRK: